Bronchiolitis Clinical Trials 2023

Bronchiolitis Clinical Trials 2023

Bronchiolitis research studies recruiting patients in 2023 need your help. Receive premium care & cutting edge treatments by enrolling in bronchiolitis clinical trials today.

Phoenix, Arizona

Procedure

Positive Airway Pressure nebulization +1 More for Bronchiolitis

Recruiting1 award1 criteria
Phoenix, Arizona

Hypothesis: That administration of nebulized therapy for bronchiolitis when using positive airway pressure is superior to standard mask ventilation in reducing hospital admissions. Bronchiolitis is a lower respiratory tract infection (LRTI) syndrome caused by a variety of different viruses. It is the most common LRTI in children under 24 months old. Multiple studies have documented variation in treatment, hospitalization rates, and length of hospital stay for bronchiolitis, suggesting a lack of consensus and an opportunity to improve care for this common disorder. Research to determine optimal delivery methods of respiratory medications that may augment oxygenation by decreasing atelectasis (Lung cell collapse) and increasing oxygen saturation have not been done. Currently bronchodilators are delivered through a passive process, inhaled as they are nebulized (made from liquid into gas) into a face mask. This study will evaluate whether using a newly developed positive pressure nebulization device that uses pressure to expand lung cells and, hypothetically, deliver the medication better, improves oxygenation by reducing atelectasis (lung cell collapse) to decrease hospitalization in infants with moderate to severe bronchiolitis. Positive pressure nebulization is a relatively new adaptation of a previously existing modality, and is already currently in use here at PCH.

Trials for Bronchiolitis Obliterans Patients

Trials for BO Patients

Phase 3 Trials

Trials With No Placebo

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to bronchiolitis

What are the top hospitals conducting bronchiolitis research?

Bronchiolitis, a common respiratory infection affecting infants and young children, has prompted several leading hospitals to undertake clinical trials in search of improved treatments. Among these institutions is the esteemed Cleveland Clinic in Cleveland, which currently has six active bronchiolitis trials underway, building upon its earlier accomplishment of eight completed studies since recording its first trial in 2008. Meanwhile, Baylor University Medical Center in Dallas is making noteworthy strides with four ongoing bronchiolitis trials, marking their involvement and commitment since initiating their initial trial back in 2015.

In Houston's medical landscape lies Houston Methodist Hospital—a facility that recognizes the importance of combating bronchiolitis through research. This hospital currently conducts four active clinical trials for this condition while maintaining an equal number of previously held investigations. Their journey began just two years ago with their inaugural bronchiolitis trial in 2019. Similarly dedicated to advancing knowledge about this troubling illness is Banner Health located in Phoenix; they too are actively involved with three current bronchiolitis studies and have contributed to our understanding by undertaking three previous investigations starting from 2019 as well.

Last but not least on this list stands Stanford University Hospital situated amidst Palo Alto's renowned medical community. Despite having only started recording data on bronchiolitis clinical trials a couple of years ago—just like Hospital #3 and #4—they are already conducting three active studies for the condition while having accomplished an equivalent number thus far.

Research conducted at these top-tier hospitals signifies significant progress towards improving outcomes for those affected by bronchiolitis, particularly vulnerable infants and children who bear the brunt of this respiratory infection's impact. The dedication displayed by these institutions underscores their commitment to pioneering innovative treatments and potentially revolutionizing care for countless young patients worldwide facing this challenging condition.

Which are the best cities for bronchiolitis clinical trials?

When it comes to bronchiolitis clinical trials, several cities emerge as key hubs for research. Philadelphia, Pennsylvania leads the way with 11 active trials investigating treatments like itacitinib and Liposomal Cyclosporine A. Houston, Texas and Boston, Massachusetts closely follow with 9 ongoing studies each focused on interventions such as Audit & Feedback (unit level) and Cohort A: Belumosudil + Standard of Care Medications. Columbus, Ohio and Dallas, Texas also contribute to the advancement of bronchiolitis care through their ongoing trials exploring various treatments including ARINA-1 plus standard of care. These cities provide individuals affected by bronchiolitis access to cutting-edge clinical trials that pave the way for improved treatment options in the future.

Which are the top treatments for bronchiolitis being explored in clinical trials?

Exciting advancements are underway in the exploration of treatments for bronchiolitis, with two standout contenders leading the way in current clinical trials. Liposomal Cyclosporine A, introduced in 2019, has shown promise and is currently being tested in two ongoing trials specifically for bronchiolitis. Similarly, Itacitinib, making its debut in 2020, is also being investigated through two active trials dedicated to this respiratory condition. As researchers delve deeper into these potential therapies and gather valuable data from their studies, there is hope that new avenues for managing bronchiolitis will soon be within reach.

What are the most recent clinical trials for bronchiolitis?

Recent clinical trials for bronchiolitis have shown promising developments in the field of treatment. Sirolimus, a drug currently undergoing Phase 2 trials, holds potential as a therapeutic option for this respiratory condition. In addition, the ARINA-1 trial is evaluating the efficacy of ARINA-1 combined with standard care in Phase 3 studies. Another notable study investigated Ruxolitinib's effectiveness and safety in treating bronchiolitis during its Phase 2 stage. Additionally, magnesium sulfate has undergone both Phase 2 and Phase 3 trials to assess its impact on bronchiolitis management. Lastly, Itacitinib is being evaluated through a Phase 1 trial to determine its feasibility as a treatment option for bronchiolitis patients. These ongoing investigations bring hope for improved outcomes and better quality of life for individuals affected by this condition.

What bronchiolitis clinical trials were recently completed?

Stanford University recently completed a clinical trial investigating the potential of Pirfenidone 267 MG [Esbriet] in treating bronchiolitis. This significant milestone marks an important step towards improved treatments for this respiratory condition.